Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis

By LabMedica International staff writers
Posted on 01 Sep 2026

Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. More...

A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies before assigning a diagnosis. Saliva offers a non-invasive sample type that can be collected repeatedly across disease stages, making it well suited for biomarker research aimed at clarifying disease status over time. Building on this potential, a new project will examine salivary biomarkers to support diagnosis and risk stratification in Long COVID.

UNC Adams School of Dentistry (University of North Carolina; Chapel Hill, NC, USA) has received an R01 grant from the National Institutes of Health (NIH) to determine whether biomarkers in saliva can diagnose long COVID and predict which acutely infected patients are likely to develop persistent symptoms. The effort will also analyze saliva collected during acute COVID-19 to evaluate signatures associated with future long COVID. The goal is to translate salivary changes into clinically actionable markers for patient classification.

The team will analyze saliva for immune and host-response signals, including proteins, metabolic mediators, and microbes, and use a machine learning pipeline to identify oral signatures of disease. By processing large patient datasets, the models are expected to improve understanding of Long COVID pathogenesis and help distinguish recovery from persistent illness. The project builds on earlier work in which the group evaluated antiseptic rinses to reduce salivary viral load in dental settings and, after collecting saliva from hundreds of patients, began investigating how SARS-CoV-2 affects the oral immune environment.

Study plans include recalling additional participants and enrolling newly infected patients who will be followed through serial saliva collection. At least three months after infection, participants will complete validated symptom questionnaires and be grouped as fully recovered or showing signs of Long COVID. Their saliva samples, linked with health histories, will then be analyzed to determine how salivary proteins, metabolic mediators, and microbes are associated with Long COVID outcomes.

Preliminary analyses of banked early-infection samples showed altered salivary protein and metabolite profiles among individuals who later developed Long COVID. Proteomic testing also identified dozens of differentially expressed proteins related to oral inflammation, oxidative stress responses, and immune dysregulation. If validated, the researchers note, these salivary biomarkers could support diagnostic and prognostic tools and help identify higher-risk patients for more proactive management during acute infection.

“Based on preliminary results, patients who develop long COVID had significantly altered salivary protein and metabolite profiles relative to patients who recovered. Proteomics results identified 47 differentially expressed proteins between severe long COVID patients and controls. There were several unexpected highly abundant proteins associated with oral inflammation, oxidative stress response, and immune dysregulation. These are interdependent mechanisms perpetuating a chronic cycle of cellular damage that may drive Long COVID pathology that we could identify in saliva during acute infection- which is pretty amazing!” said Laura Jacox, DMD, PhD, MS.

“For patients who have long-term long COVID symptoms, it would be wonderful to provide a non-invasive diagnostic test. This would save efforts and costs that are currently being spent ruling out other potential causes, and a test provides comfort to patients and informs providers,” said Jacox.

Related Links
UNC Adams School of Dentistry


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Quantitative lmmunoassay Test Menu
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.